Advances in immune neoadjuvant/adjuvant therapy-related adverse events of non-small cell lung cancer

Lung cancer has been the leading cause of cancer-related death for decades and years. For the patients with early stage non-small cell lung cancer, surgical resection is the mainstay of therapy. Treatment before and after surgery, such as chemotherapy, can bring benefit to these patients, improving the 5 years survival rate by 5% approximately. Recently, the advent of immunotherapy significantly improved prognosis for the patient with lung cancer. Programmed death 1 and its ligand have become a powerful treatment option for lung cancer. In this review, we will discuss the role immunotherapy played in preoperative neoadjuvant and postoperative adjuvant treatment in lung cancer.